2024-03-29T11:21:33Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/70192022-10-10T10:20:26Zcom_20.500.12105_2145com_20.500.12105_2051com_20.500.12105_2144col_20.500.12105_2147
Repisalud
author
Fernandez-Jimenez, Rodrigo
author
Latina, Jacqueline
author
Hajjar, Roger
author
Fuster, Valentin
author
Wang, Thomas
author
Blot, William
funder
American Heart Association
funder
Unión Europea. Comisión Europea
funder
Ministerio de Ciencia, Innovación y Universidades (España)
2019-01-29T14:17:32Z
2019-01-29T14:17:32Z
2018-03
J Am Coll Cardiol. 2018; 71(11):Supplement, page A1892
0735-1097
http://hdl.handle.net/20.500.12105/7019
10.1016/S0735-1097(18)32433-1
Journal of the American College of Cardiology
Background: There are little data on the role of aspirin for primary prevention of cardiovascular disease (CVD) in racial groups. Our objective was to study the association between aspirin use patterns and CVD incidence by race in the Southern Community Cohort Study.
Methods: A total of 44,177 adults (mean age 52.2 ± 8.6 years, 66.6% female, 67.4% blacks and 32.6% whites) with no history of CVD enrolled from 2002 through 2009 were followed for a median of 9.2 years. At cohort entry, the simplified 10-year Framingham risk was calculated, and data related to aspirin use and other socioeconomic covariates collected. Race-specific adjusted odds ratios (aOR) for aspirin use and hazard ratios (aHR) for first major adverse cardiac event (MACE) were estimated by using multivariate logistic and Cox regression models.
Results: Blacks were less likely to take aspirin as compared to whites (aOR 0.80; 95% CI 0.76-0.84). Incidence rates of MACE were 8.23 (95% CI 7.73-8.75) vs. 6.85 (95% CI 6.55-7.17) per 1000 person-year in whites and blacks, respectively. Overall, aspirin use was associated with increased MACE (aHR 1.22; 95%
CI 1.12-1.33). Notably, in the group of high risk individuals aged 50 to 69 years, aspirin use was associated with significantly increased first MACE in blacks, especially in women, but not in whites (Table).
Conclusion: Blacks were less likely to take aspirin for primary prevention of CVD. Aspirin use was associated with an increased incidence of MACE, more so in blacks than whites in this high-risk population.
eng
Aspirin
Prevention
Racial disparities
Low Dose Aspirin for Primary Prevention of Cardiovascular Disease: Use Patterns and Impact Across Race in the Southern Community Cohort Study
conference poster
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
URL
https://repisalud.isciii.es/bitstream/20.500.12105/7019/1/Disparities%20aspirin_ACC%202018_FINAL.pdf
File
MD5
96017c7594841b96aac448a7e328c7fa
615249
application/pdf
Disparities aspirin_ACC 2018_FINAL.pdf
URL
https://repisalud.isciii.es/bitstream/20.500.12105/7019/3/Disparities%20aspirin_ACC%202018_FINAL.pdf.txt
File
MD5
a62bb75575cd941d7b989c0c08b1016a
1923
text/plain
Disparities aspirin_ACC 2018_FINAL.pdf.txt